• Radnostix closed the acquisition of key assets from Lucerno Dynamics, adding the LARA System platform, ELLEXA Explorer software, and related IP.
• Assets target monitoring of IV radiopharmaceutical administration, aiming to reduce extravasations; portfolio also supports uptake, dosimetry, quantification.
• Transaction expands Radnostix’s radiopharma medical device portfolio, positioning it to develop delivery and monitoring tools for theranostics clinics.
• Lucerno said the LARA System and ELLEXA software have been used in nearly 50,000 administrations across the US, Europe, and Asia-Pacific.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radnostix Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607021042PR_NEWS_USPR_____CL97217) on July 02, 2026, and is solely responsible for the information contained therein.